ALK-TKIs have been shown to be a strong therapeutic option for patients with ALK- or ROS1-rearranged NSCLC; nonetheless, the emergence of resistance mechanisms still represents the main obstacle to overcome. Here, ROS1 is linked to non-small cell lung carcinoma.